CK Cooper: A Buying Opportunity In ENZN
Analysts at CK Cooper reiterate their "buy" rating on Enzon Pharmaceuticals Inc (NASDAQ: ENZN). The target price for ENZN is set to $18.
ENZN has posted its Q1 EPS and revenues significantly higher than the estimates. The analysts are “enthused at how well the company has transitioned through a major strategic change over the past quarter since the sale of their specialty pharmaceutical business.”
CK Cooper recommends investors to make use of the buying opportunity as the company is planning “to return value to shareholders from a significant portion of their $363.01 mm in net cash and a PEGINTRON royalty stream that we currently value at $275.15 mm.”
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We're Loving
